光韵达 reported revenue of ¥1.09B for the period ended 2026-06-30, +117.9% year on year. Net income was ¥0.01B, a 0.9% net margin on a 26.9% gross margin. The largest revenue line is 电子制造服务 at 36% of the total. Free cash flow for the period was ¥-0.05B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.09B | +117.9% |
| Gross profit | ¥0.29B | — |
| Operating income | ¥0.02B | — |
| Net income | ¥0.01B | +59.6% |
| Gross margin | 26.9% | Net margin 0.9% |
| Revenue Q/Q | +53.9% | — |
| Segment | Revenue | Share |
|---|---|---|
| 电子制造服务 | ¥0.40B | 36.5% |
| 通信终端 | ¥0.37B | 33.8% |
| 航空零部件 | ¥0.18B | 16.5% |
| 其他 | ¥0.12B | 10.7% |
| 激光器 | ¥0.03B | 2.6% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.79B | 73.1% |
| R&D | ¥0.06B | 5.5% |
| SG&A | ¥0.32B | 29.0% |
| Tax & other | ¥0.01B | 1.0% |
| Item | Amount |
|---|---|
| Total assets | ¥4.72B |
| Total liabilities | ¥2.89B |
| Shareholders' equity | ¥1.83B |
| Equity / assets | 38.8% |
| Operating cash flow | ¥-0.02B |
| Capital expenditure | ¥0.04B |
| Free cash flow | ¥-0.05B |
| Cash conversion (OCF / net income) | -1501% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
富瑞特装 ・ 拓尔思 ・ 永利股份 ・ 银信科技 ・ 洲明科技 ・ 金城医药 ・ 开尔新材 ・ 方直科技 ・ 上海新阳 ・ ST美晨 ・ 冠昊生物 ・ 东宝生物
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies